Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health Chief Technology Officer Darya Chudova reported routine equity compensation activity involving restricted stock units and related tax withholding. On July 1, 2026, several restricted stock unit awards converted into common stock, reflected as multiple exercise transactions.
In connection with the vesting, 4,318 shares of common stock were retained by Guardant Health at $170.77 per share to cover her tax withholding obligations, as described in the footnotes. Following these transactions, Chudova directly held 78,373 shares of Guardant Health common stock.
Guardant Health, Inc.’s Chief Financial Officer Michael Brian Bell reported routine equity compensation activity involving restricted stock units that vested into common stock. On July 1, 2026, RSU conversions delivered 7,278 shares of common stock, while 3,914 shares were withheld at $170.77 per share to cover tax obligations, rather than sold in the open market.
Guardant Health, Inc. director and Co-Chief Executive Officer Helmy Eltoukhy, through the Helmy A. Eltoukhy Revocable Trust, reported routine equity compensation activity involving restricted stock units and related tax withholding.
On June 30 and July 1, 2026, a total of 36,529 restricted stock units were converted into an equal number of shares of common stock at a conversion price of $0.00 per share. To satisfy tax withholding obligations tied to these vestings, 18,514 shares of common stock were retained by the company at prices of $150.03 and $170.77 per share, as noted in the footnotes. These F-code dispositions reflect payment of tax liabilities rather than open-market sales.
Guardant Health, Inc. Co-Chief Executive Officer AmirAli Talasaz reported routine equity compensation activity involving restricted stock units. On June 30 and July 1, 2026, a total of 36,529 restricted stock units converted into common stock through derivative exercises, reflecting scheduled vesting.
Across the same dates, 18,514 common shares were withheld and retained by the company at prices of $150.03 and $170.77 per share to cover tax liabilities associated with these vesting events. The transactions occurred through the Talasaz and Eskandari 2017 Family Trust and do not involve any open-market purchases or sales.
Guardant Health director Steve E. Krognes reported an exercise of restricted stock units that delivered 155 shares of common stock on June 30, 2026. These RSUs were from an award granted on August 9, 2022, which vested 25% on June 30, 2023 and the remaining 75% over the following three years.
After this derivative exercise, Krognes directly holds 14,580 shares of Guardant Health common stock. This Form 4 reflects a compensation-related vesting and conversion of equity awards, with no open-market buying or selling reported in this filing.
Guardant Health filed a Form 144 reporting proposed resale of 4,000 shares of Common Stock via a cashless employee option exercise on 07/01/2026. The filing also lists recent open-market sales by Meghan V. Joyce totaling 20,203 shares across June 2026 with proceeds shown per trade.
Guardant Health Chief Information Officer Kumud Kalia reported small, offsetting insider trades in company common stock. On June 10 and June 15, Kalia executed open-market sales totaling 1,200 shares at prices around $130–$131 per share and an open-market purchase of 600 shares at about $130.76 per share.
After these transactions, Kalia directly holds 40,814 shares of Guardant Health common stock. A footnote states that, based on these trades, the company identified recoverable Section 16(b) short-swing profits of $192, which Kalia has paid back to the company.
Guardant Health, Inc. co-CEO AmirAli Talasaz reported a combination of stock option exercises and share sales tied to the Talasaz and Eskandari 2017 Family Trust. On June 26 and June 29, 2026, the trust sold an aggregate 260,000 shares of common stock in open-market transactions at weighted-average prices around $150–$153 per share, executed across multiple price ranges.
On the same dates, stock options to acquire a total of 254,832 shares of common stock were exercised at a $4.18 per-share exercise price, converting derivative awards into common shares. The common stock and options are reported as held directly or indirectly, with a significant portion attributed to the Talasaz and Eskandari 2017 Family Trust.
GH reporting person AmirAli Talasaz submitted a Form 144 disclosing secondary sales of Common Stock. The filing lists two dispositions: 50,000 shares sold on 05/12/2026 for $5,016,000 and 210,000 shares sold on 05/20/2026 for $23,076,690. The broker named is Stifel Nicolaus & Company Inc. The filing also lists holdings/issuable amounts tied to earlier grants: 5,168 Founder Shares (09/22/2018) and 254,832 shares related to an equity compensation event (04/23/2017).
Guardant Health, Inc. submission of a Form 144 notifies the SEC of proposed sale of 2000 shares of Common Stock on 06/26/2026 related to an Employee Stock Option Exercise via a broker payment for cashless exercise.
The excerpt also lists recent dispositions by Meghan V. Joyce: 10,000 shares on 06/03/2026, 6,203 shares on 06/22/2026, and 2,000 shares on 06/24/2026, with proceeds shown in the filing for each transaction.